[Cost-effectiveness analysis of ocriplasmin in the treatment of vitreomacular traction in Italy]
DOI:
https://doi.org/10.7175/fe.v16i4.1221Keywords:
Ocriplasmin, Vitreomacular traction, Macular holeAbstract
BACKGROUND: Vitreomacular traction (VMT) caused by vitreomacular adhesion (VMA), is a pathological condition when the vitreous humor has an abnormally strong attachment to the central part of the retina. Ocriplasmin recently approved for the treatment of VMT, including when associated with macular hole (MH) of diameter less than or equal to 400 microns, is a recombinant truncated form of the human serine protease plasmin with retained enzymatic activity, administered by intravitreal injection. We estimated long-term benefits and costs associated with the resolution of traction, following treatment with ocriplasmin versus Standard of Care (SoC), from National Health Service (NHS) perspective.
METHODS: A lifetime Markov model has been adopted for Italy in order to estimate costs and outcomes, gained for patients with VMT, with and without MH, treated with ocriplasmin. Health effects have been expressed as Life Years (LY) and Quality adjusted LY gained (QALY), and estimated based on time spent in Visual Acuity (VA) states, defined by best and worst seeing eye, disutility impact associated with surgical interventions, adverse events and metamorphopsia. Deterministic
and probabilistic analysis have also been conducted.
RESULTS: Over a lifetime ocriplasmin versus SoC generated incremental benefits in terms of QALYs and overall treatment costs in each patients subgroups. Patients with VMT and VMT+MH treated with ocriplasmin had an incremental survival benefits of 0.1123 and 0.0772 QALYs respectively. Therefore, it is expected to come at an incremental cost of 1,873 € and 2,185 € for VMT and VMT+MH patients respectively. The associated ICER is 16,683 € and 28,294 € per QALY gained. Both sensitivity analyses for each of the subgroups confirmed the robustness of the model results.
CONCLUSION: Compared to SoC, ocriplasmin is a cost effective therapy option in the treatment of VMT, including when
associated with MH.
[Article in Italian]
References
Girach A, Pakola S. Vitreomacular Interface Diseases: Pathophysiology, Diagnosis and Future Treatment Options. Expert Rev Ophthalmol 2012; 7: 311-23; http://dx.doi.org/10.1586/eop.12.34
Bandello F, Arpa P, Azzolini C, et al. Documento di consenso: Gestione diagnostica e clinica delle trazioni vitreomaculari. Disponibile on line su: http://www.fondazionebietti.it/sites/default/files/pdf/documento_consenso_trazioni_vitreomaculari.pdf
Steel DHW, Lotery AJ. Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment. Eye (Lond) 2013; 27(Suppl 1): S1-S2; http://dx.doi.org/10.1038/eye.2013.212
García-Layana A, García-Arumí J, Ruiz-Moreno M, et al. A review of current management of vitreomacular traction and macular hole. J Ophthalmol 2015; 2015: 809640; http://dx.doi.org/10.1155/2015/412903
Duker JS, Kaiser PK, Binder S, et al. The international vitreomacular traction study group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 2013; 120: 2611-9; http://dx.doi.org/10.1016/j.ophtha.2013.07.042
European Medicine Agency (EMA). European public assessment report: ocriplasmina. 2015, EMA/177035/2015
Stalmans P, Benz MS, Gandorfer A, et al.; for the MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012; 367: 606-15; http://dx.doi.org/10.1056/NEJMoa1110823
Singh RP, Li A, Bedi R, et al. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 2014; 98: 356-60; http://dx.doi.org/10.1136/bjophthalmol-2013-304219
Meyer JC, Shah GK, Blinder KJ, et al. Early Evolution of the Vitreomacular Interface and Clinical Efficacy After Ocriplasmin Injection for Symptomatic Vitreomacular Adhesion. Ophthalmic Surg Lasers Imaging Retina 2015; 46: 209-16; http://dx.doi.org/10.3928/23258160-20150213-21
Willekens K, Abegão Pinto L, et al. Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology. Retina 2015; 35: 1135-43; http://dx.doi.org/10.1097/iae.0000000000000507
NICE technology appraisal guidance 297.Ocriplasmin for treating vitreomacular traction. Disponibile online su: https://www.nice.org.uk/guidance/ta297/resources/ocriplasmin-for-treating-vitreomacular-traction-82600738429381
NICE Guidance. Ocriplasmin is not effective in patients with ERM. The use of ocriplasmin in people with vitreomacular traction with an epiretinal membrane, but without a stage II macular hole, is not a cost-effective use of NHS resources. Disponibile online su: https://www.nice.org.uk/donotdo/ocriplasmin-is-not-effective-in-patients-witherm-the-use-of-ocriplasmin-in-people-withvitreomacular-traction-with-an-epiretinal-membrane-but-without-a-stage-iimacular-hole-is-not-a-costeffective-use
Payakachat N, Summers K, Pleil A, et al. Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration. Qual Life Res 2009; 18: 801-13; http://dx.doi.org/10.1007/s11136-009-9499-6
Tosh J, Brazier J, Evans P, et al. A Review of Generic Preference-Based Measures of Health-Related Quality of Life in Visual Disorders. Value in Health 2012; 15: 118-27; http://dx.doi.org/10.1016/j.jval.2011.08.002
Czoski-Murray C, Carlton J, Brazier J, et al. Valuing condition-specific health states using simulation contact lenses. Value in Health 2009; 12: 793-9; http://dx.doi.org/10.1111/j.1524-4733.2009.00527.x
Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. GU Serie Generale n.23 del 28-1-2013 - Suppl. Ordinario n. 8
Riclassificazione del medicinale per uso umano «Jetrea», ai sensi dell’articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. Determina n. 578/2015. GU Serie Generale n.121 del 27-5-2015
Fukuda S, Okamoto F, Yuasa M, et al. Vision-related quality of life and visual function in patients undergoing vitrectomy, gas tamponade and cataract surgery for macular hole. Br J Ophthalmol 2009; 93: 1595-9; http://dx.doi.org/10.1136/bjo.2008.155440
Brown G, Brown M, Brown H, et al. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Opthalmology 2007; 114: 1170-8; http://dx.doi.org/10.1016/j.ophtha.2006.09.019
Busbee B, Brown M, Brown G, et al. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology 2002; 109: 606-12; http://dx.doi.org/10.1016/S0161-6420(01)00971-X
Brändle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther 2007; 45: 203-20; http://dx.doi.org/10.5414/CPP45203
Mantovani LG. Health technology assessment. Principi, concetti, strumenti operative. Milano: Il Sole 24 Ore Sanità, 2011
Fattore G. Proposte di linee guida per la valutazione economica degli interventi sanitari. PharmacoEconomics Italian Research Articles 2009; 11: 83-93
Chang JS, Smiddy WE. Cost Evaluation of Surgical and Pharmaceutical Options in Treatment for Vitreomacular Adhesion and Macular Holes. Ophthalmology 2014; 12: 1720-6; http://dx.doi.org/10.1016/j.ophtha.2014.03.029
Lafuma A, Brezin A, Lopatriello S, et al. Evaluation of non medical costs associated with visual impairment in four European countries (France, Italy, Germany and the United Kingdom). Pharmacoeconomics 2006; 24:193-205
Published
Issue
Section
License
>> DISTRIBUTION / LICENSE <<
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
